Suppr超能文献

多塞平在改善失眠障碍患者的执行功能方面比唑吡坦更有效。

Doxepin is more effective than zolpidem in improving executive function in patients with insomnia disorder.

机构信息

Department of Medical Psychology, Hangzhou Seventh People's Hospital, Hangzhou, 310013, China.

Affiliated Mental Health Center, Zhejiang University School of Medicine, Hangzhou, 310013, China.

出版信息

Sleep Breath. 2024 May;28(2):929-934. doi: 10.1007/s11325-023-02972-4. Epub 2023 Dec 20.

Abstract

UNLABELLED

BACKGROUND : Insomnia disorder is associated with an impairment in cognitive performance. Doxepin and zolpidem have been found to be effective in improving sleep. In this study, we aimed to compare the effects of doxepin and zolpidem on sleep structure and executive function in patients with insomnia disorder.

METHODS

Patients with primary insomnia were randomly assigned to receive doxepin 6 mg/day orally or zolpidem 5-10 mg/day orally. Polysomnography (PSG) and the Pittsburgh Sleep Quality Index (PSQI) were used at baseline and after the 8-week treatment to compare clinical efficacy in the two groups. Safety was assessed using the Treatment Emergent Symptom Scale (TESS). Executive function was evaluated using the Wisconsin sorting card test (WSCT).

RESULTS

Of 120 patients enrolled in the study, 60 participants were assigned to each group. A total of 109 participants (53 in the doxepin group and 56 in the zolpidem group) completed the study. After treatment, the wake after sleep onset (WASO) and total sleep time (TST) values in the doxepin group were 80.3 ± 21.4 min and 378.9 ± 21.9 min, respectively, which were significantly better than those in the zolpidem group (132.9 ± 26.5 min and 333.2 ± 24.2 min, respectively; (P < 0.05)). The sleep onset latency (SOL) value in the zolpidem group (20.3 ± 4.7 min) was significantly better than that in the doxepin group (28.2 ± 5.6 min; P < 0.05). The sleep efficiency (SE) in the doxepin group was 77.8 ± 4.2%, which was significantly better than that in the zolpidem group (68.6 ± 5.0%; P < 0.05). The PSQI score of the doxepin group was 6.1 ± 1.1, which was significantly lower than that in the zolpidem group (7.9 ± 1.9; P < 0.05). The treatment adverse events in the doxepin group was 23.3%, which was significantly higher than that in the zolpidem group (13.3%; P < 0.05). The WSCT showed a significant improvement in persistent errors (PE), random errors (RE), and categories in the two groups after 8-week treatment, and the improvement in RE and the categories was more obvious in the doxepin group (P < 0.05).

CONCLUSIONS

Both doxepin and zolpidem were found to be effective in improving sleep quality, but the effects exhibited different patterns. Doxepin improved executive function more effectively than zolpidem in patients with insomnia disorder.

摘要

研究背景:失眠障碍与认知表现受损有关。多塞平和唑吡坦已被证明能有效改善睡眠。本研究旨在比较多塞平和唑吡坦对失眠障碍患者睡眠结构和执行功能的影响。

研究方法:将原发性失眠患者随机分为每日口服多塞平 6mg 或唑吡坦 5-10mg。基线和 8 周治疗后使用多导睡眠图(PSG)和匹兹堡睡眠质量指数(PSQI)比较两组的临床疗效。使用治疗中出现的症状量表(TESS)评估安全性。使用威斯康星卡片分类测验(WSCT)评估执行功能。

研究结果:在纳入的 120 名患者中,每组有 60 名参与者。共有 109 名参与者(多塞平组 53 名,唑吡坦组 56 名)完成了研究。治疗后,多塞平组的入睡后觉醒时间(WASO)和总睡眠时间(TST)分别为 80.3±21.4min 和 378.9±21.9min,明显优于唑吡坦组(132.9±26.5min 和 333.2±24.2min;均 P<0.05)。唑吡坦组的睡眠潜伏期(SOL)值(20.3±4.7min)明显优于多塞平组(28.2±5.6min;P<0.05)。多塞平组的睡眠效率(SE)为 77.8±4.2%,明显优于唑吡坦组(68.6±5.0%;P<0.05)。多塞平组的 PSQI 评分为 6.1±1.1,明显低于唑吡坦组(7.9±1.9;P<0.05)。多塞平组的治疗不良事件发生率为 23.3%,明显高于唑吡坦组(13.3%;P<0.05)。WSCT 显示两组治疗 8 周后持续错误(PE)、随机错误(RE)和分类均有显著改善,多塞平组的 RE 和分类改善更为明显(P<0.05)。

研究结论:多塞平和唑吡坦均能有效改善睡眠质量,但效果表现不同。多塞平在改善失眠障碍患者的执行功能方面比唑吡坦更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验